Note 9 - Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2020

Notes Tables

Share-based Payment Arrangement, Option, Activity [Table Text Block]

	Year Ended December 31, 2020					Year Ended December 31, 2019
	Shares			Wtd. Avg. Exercise Price		Shares			Wtd. Avg. Exercise Price
Outstanding at beginning of year		1,570,455		$	1.96		2,043,402		$	1.91
Granted		-			-		-			-
Exercised		(726,000	)		1.91		(469,510	)		1.72
Forfeited		-			-		(3,437	)		5.69
Outstanding at end of year		844,455		$	2.00		1,570,455		$	1.96
Stock options exercisable at year end		832,478		$	1.98		1,465,599		$	1.94

	Year Ended December 31, 2020					Year Ended December 31, 2019
	Shares			Wtd. Avg. Exercise Price		Shares			Wtd. Avg. Exercise Price
Outstanding at beginning of year		737,497		$	1.64		964,997		$	1.64
Granted		-			-		-			-
Exercised		(51,496	)		1.64		(227,500	)		1.64
Outstanding at end of year		686,001		$	1.64		737,497		$	1.64
Stock options exercisable at year end		686,001			1.64		737,497			1.64

Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Range of Exercise Prices				Number Outstanding at December 31, 2020		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price
	$0.49	-	1.00		3,571		0.91	$	0.49
	$1.01	-	1.50		110,449		0.78		1.19
	$1.51	-	2.50		676,367		4.07		1.95
	$2.51	-	8.60		54,068		4.64		4.49
					844,455		3.66	$	2.00

Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]

	Year Ended December 31, 2020					Year Ended December 31, 2019
	Shares			Wtd. Avg. Grant Date Fair Value		Shares			Wtd. Avg. Grant Date Fair Value
Outstanding at beginning of year		429,399		$	13.25		279,919		$	5.00
Granted		717,267			20.88		309,218			17.15
Granted in lieu of cash		34,154			9.18		-			-
Vested		(208,858	)		11.32		(125,818	)		4.57
Forfeited		(41,108	)		15.47		(33,920	)		12.88
Non-vested at end of year		930,854		$	19.31		429,399		$	13.25

	Year Ended December 31, 2020
	Shares			Wtd. Avg. Grant Date Fair Value
Outstanding at beginning of year		-		$	-
Granted		82,805			9.18
Vested		(82,805	)		9.18
Non-vested at end of year		-		$	-

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Year Ended December 31,
(In thousands)	2020		2019
Research and development costs	$	1,012	$	571
Sales and marketing costs		852		711
General and administrative costs		3,518		1,584
Cost of revenue		599		177
Total	$	5,981	$	3,043